Abstract
A large body of evidence point out that the onset of synthetic lethality may provide a useful tool for amplifying the efficacy of drugs in anticancer regimens, to uncover interdependence between genes and to identify predictive factors that would be extremely useful to guide in the selection of more effective targeted drugs and drug combinations for each patient. Here, we provide an overview on the exploitation of synthetic lethality to overcome drug resistance to conventional chemotherapy in several types of solid tumors. We report recent findings on cellular markers and gene mutations which are specifically essential for the viability of cancer cells and for resistance to chemotherapeutics. In addition, new molecularly targeted strategies to overcome drug resistance are suggested.
Keywords: Synthetic lethality, drug resistance, solid tumors, PARP inhibitors, DNA repair pathway, anticancer therapy, anticancer regimens, genes, cellular markers, cancer cells
Current Medicinal Chemistry
Title:Synthetic Lethality to Overcome Cancer Drug Resistance
Volume: 19 Issue: 23
Author(s): L. Porcelli, A. E. Quatrale, P. Mantuano, N. Silvestris, A. E. Brunetti, H. Calvert, A. Paradiso and A. Azzariti
Affiliation:
Keywords: Synthetic lethality, drug resistance, solid tumors, PARP inhibitors, DNA repair pathway, anticancer therapy, anticancer regimens, genes, cellular markers, cancer cells
Abstract: A large body of evidence point out that the onset of synthetic lethality may provide a useful tool for amplifying the efficacy of drugs in anticancer regimens, to uncover interdependence between genes and to identify predictive factors that would be extremely useful to guide in the selection of more effective targeted drugs and drug combinations for each patient. Here, we provide an overview on the exploitation of synthetic lethality to overcome drug resistance to conventional chemotherapy in several types of solid tumors. We report recent findings on cellular markers and gene mutations which are specifically essential for the viability of cancer cells and for resistance to chemotherapeutics. In addition, new molecularly targeted strategies to overcome drug resistance are suggested.
Export Options
About this article
Cite this article as:
Porcelli L., E. Quatrale A., Mantuano P., Silvestris N., E. Brunetti A., Calvert H., Paradiso A. and Azzariti A., Synthetic Lethality to Overcome Cancer Drug Resistance, Current Medicinal Chemistry 2012; 19 (23) . https://dx.doi.org/10.2174/092986712802002563
DOI https://dx.doi.org/10.2174/092986712802002563 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tissue Distribution and Pharmacodynamics: A Complicated Relationship
Current Drug Metabolism Reducing the Burden of Cervical Cancer in the Developing World
Current Women`s Health Reviews Folic Acid Conjugated Nanocarriers for Efficient Targetability and Promising Anticancer Efficacy for Treatment of Breast Cancer: A Review of Recent Updates
Current Pharmaceutical Design Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to "Work it Out"?
Current Pharmaceutical Design Synthesis and Evaluation of Estradiol Derivatives as Anti-Breast Cancer Agents
Letters in Drug Design & Discovery Synthesis of New Thioureas Derivatives and Evaluation of Their Efficacy as Proliferation Inhibitors in MCF-7 Breast Cancer Cells by Using <sup>99m</sup>Tc-MIBI Radiotracer
Medicinal Chemistry Meet Our Editorial Board Member
Current Nanomedicine Effects of Crosstalks Between Sumoylation and Phosphorylation in Normal Cellular Physiology and Human Diseases
Current Molecular Medicine The Possible Existence of a Gut-Bone Axis Suggested by Studies of Genetically Manipulated Mouse Models?
Current Pharmaceutical Design Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management
Cardiovascular & Hematological Disorders-Drug Targets Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics Delineation of Current Development of Antimitotic Compounds Targeting Cytoskeletal Protein Tubulin and Microtubule in the Cancer Therapy
Current Chemical Biology Pain Biomarkers in Cancer: An Overview
Current Pharmaceutical Design Implications of Photophysical and Physicochemical Factors on Successful Application of Photodynamic Therapy
Current Pharmaceutical Design Effects of Intermittent Hypoxia on Expression of Glucose Metabolism Genes in MCF7 Breast Cancer Cell Line
Current Cancer Drug Targets Gene Sets of Gene Ontology are More Stable Diagnostic Biomarkers than Genes in Oral Squamous Cell Carcinoma
Current Bioinformatics Therapeutic Antibodies
Current Molecular Medicine Efficient Growth Inhibition of Human Osteosarcoma Cells Using a Peptide Derived from the MDM-2-Binding Site of p53
Protein & Peptide Letters Therapeutic Exploitation of Apoptosis and Autophagy for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry